LAB-ON-A-CHIP AND MICROARRAYS (BIOCHIP) MARKET ANALYSIS

Market News

Global Lab-on-a-chip and Microarrays (Biochip) Market: Key Developments

In March 2022, Quotient Ltd. received Conformite Europeenne (CE) Mark for MosaiQ Extended Immunohematology (IH) Microarray. The CE marking confirms that the Extended IH Microarray meets the European Medical Devices Directive (EMDD) requirements.

In December 2021, Bionano Genomics Inc. announced the launch of version 6.1 of BioDiscovery’s NxClinical software for genome analysis with capabilities for visualization, interpretation, and reporting of next-generation sequencing data in genetic diseases and cancer.

In November 2021, Parallel Fluidics announced USD 1.8 million in funding to lower the barrier to entry for microfluidic development. The company is aimed at building a platform that will lower the barrier of entry to microfluidic development by providing rapid device prototypes and solutions to these shared engineering problems and aid scientists innovate faster and improve the chances that their products will make the jump from lab to market.

In April 2021, PathogenDx Inc. revealed that the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for its patented COVID-19 multiplexed viral diagnostic assay, DetectX-Rv. DetectX-Rv is an RT-PCR and DNA microarray hybridization test intended for the qualitative detection of nucleic acids from SARS-CoV-2 swabs.